FDA Grants Full Approval to Retevmo for Advanced Thyroid Cancer
WASHINGTON, D.C. — The FDA on Wednesday granted full approval to the drug selpercatinib, marketed as Retevmo, for treating advanced thyroid cancer in both adults and children aged 2 and …
FDA Grants Full Approval to Retevmo for Advanced Thyroid Cancer Read More